Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Zydus Lifesciences beats estimates, sees high-teens growth in FY27
For FY26, its revenue from operations stood at ₹27,148.4 crore, up 17% on-year, and adjusted net profit grew 15% to ₹5,456.4 crore.
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 19 May 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 19 May 2026 - Sun Pharmaceutical Industries, BSE and PB Fintech shares.
Healthcare stock Cupid shows resilience against the stock market sell-off
Cupid share price rose 3.4% on May 18 after announcing strong Q4 FY26 results, with a 26% year-over-year income increase. The company plans aggressive growth, targeting ₹600 crore revenue in FY27 and expanding its FMCG distribution and product portfolio.
Aarti Drugs Q4 profit falls 12% despite revenue growth
Revenue rises 6.4% year-on-year; EBITDA margin remains largely stable
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 15 May 2026 - Mint
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 15 May 2026Mint
Senores Pharma Q4 Results: Stock drops 5% on sequential earnings weakness
Senores Pharmaceuticals shares fell over 5% despite strong year-on-year earnings growth, as investors reacted to sequential weakness in EBITDA and margins amid a softer operational performance in the March quarter.
Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27
Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business pressures. However, operations in India, Europe, and emerging markets show healthy growth. New launches like Semaglutide and Abatacept are expected to drive future expansion. Margins are set to improve with better product mix and cost controls.
Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividend
Cipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also declined. Despite these figures, key therapies and trade generics business showed strong growth. The company plans to focus on expanding its markets and developing its future pipeline. A final dividend of Rs 13 per equity share has been recommended.
Neuland Laboratories shares rally 7% as profit jumps seven-fold and revenue doubles in Q4
Neuland Laboratories shares saw a significant jump following a strong Q4 performance. The company reported a massive increase in profit and revenue year-on-year. This robust financial result was driven by strong business momentum across key segments. The company is also investing in future growth through strategic initiatives.
Nifty, Bank Nifty strategy; 3 stock recommendations by Motilal Oswal
Chandan Taparia of Motilal Oswal decodes how to trade Nifty and Bank Nifty today; here are stock bets and strategy
Kotak AMC’s Shibani Sircar Kurian bets on financials and healthcare; cautious on IT
Shibani Sircar Kurian, Head -Equity Research and Fund Manager at Kotak Mahindra AMC, which manages assets worth nearly $4.79 billion, said the ongoing Middle East conflict remains the biggest concern for Indian markets due to its potential impact on oil prices, growth and earnings. She said Kotak AMC remains selective, favouring financials, healthcare and parts of industrials, while staying cautious on smallcaps and Indian IT amid AI-led disruption. Disclaimer: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
Unique Picks: 6 stocks held by only one MF scheme in April, falling up to 40% in CY26
An analysis of mutual fund portfolios revealed 29 stocks held exclusively by single schemes, with most underperforming in CY26. However, Satin Creditcare Network, Rossell Techsys, and Amanta Healthcare bucked the trend, delivering strong returns. Brooks Laboratories and EFC (I) were among those experiencing significant declines.